Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.38 Analyst target: $2.75 Upside: 99.28%
BrilliA Inc. is an innovative biotechnology company dedicated to enhancing skin health and advancing regenerative medicine through cutting-edge solutions for wound healing. By harnessing proprietary technologies, BrilliA addresses significant unmet medical needs, aiming to improve patient quality of life. With a strong commitment to research and development, the company is well-positioned to transform scientific advancements into effective therapeutic products, solidifying its role as a leader in the dynamic healthcare landscape.
See the full interactive analysis & chart →Informational only — not investment advice.